Warner Chilcott has announced that it has completed the acquisition of a portfolio of patents from AGI Therapeutics plc for a purchase price of approximately $0.3 million.
"We are pleased to have acquired the intellectual property rights to a novel early stage product under development for use in the treatment of gastrointestinal conditions, including ulcerative colitis," said Roger Boissonneault, President and CEO.
Warner Chilcott is a leading specialty pharmaceutical company currently focused on the women's healthcare, gastroenterology, dermatology and urology segments of the North American and Western European pharmaceuticals markets. The Company is fully integrated with internal resources dedicated to the development, manufacturing and promotion of its products. WCRX-G.